Group 1 - The core viewpoint of the article highlights the financial performance of Haizheng Pharmaceutical for the third quarter of 2025, indicating a slight increase in revenue but a decline in net profit and earnings per share [1] Group 2 - Haizheng Pharmaceutical reported revenue of approximately 7.923 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 0.61% [1] - The net profit attributable to shareholders of the listed company was approximately 461 million yuan, showing a year-on-year decrease of 10.55% [1] - The basic earnings per share were 0.4 yuan, reflecting a year-on-year decrease of 9.09% [1] - As of the report date, Haizheng Pharmaceutical's market capitalization stood at 12.6 billion yuan [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、2025 年第三季度报告； 同意 9 票，反对 0 票，弃权 0 票。 浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）第十届 董事会第八次会议于 2025 年 10 月 27 日上午以通讯方式召开，应参加本次会议 董事 9 人，亲自参加会议董事 9 人。本次会议的召开程序符合《公司法》和《公 司章程》的规定，会议合法有效。本次会议由公司董事长肖卫红先生主持，经审 议，与会董事以通讯表决方式通过了如下决议： 一、关于计提资产减值准备的议案； 同意 9 票，反对 0 票，弃权 0 票。 详见《浙江海正药业股份有限公司关于计提资产减值准备的公告》，已登载 于 2025 年 10 月 28 日的《中国证券报》《上海证券报》《证券时报》和上海证券 交易所网站（www.sse.com.cn）上。 证券代码：600267 证券简称：海正药业 公告编号：临 2025-61 号 浙江海正药业股份有限公司 第十届董事会第八次会议决议公告 四、关于确认公司第十届董事会审计委员会成员和召 ...

Financial Performance - The company's revenue for the third quarter reached ¥2,672,459,633.39, an increase of 1.57% compared to the same period last year[4] - Total profit for the quarter was ¥215,434,956.96, representing a significant increase of 79.59% year-over-year[4] - Net profit attributable to shareholders was ¥161,858,607.96, up 102.14% compared to the same quarter last year[4] - The net profit excluding non-recurring gains and losses for the quarter was ¥169,287,578.00, reflecting a 96.13% increase year-over-year, driven by growth in sales of formulations and animal drugs[4][9] - Basic earnings per share for the quarter was ¥0.14, a 100% increase compared to the same period last year[4] - Total operating revenue for the first three quarters of 2025 reached ¥7,922,794,186.82, a slight increase from ¥7,874,540,640.41 in the same period of 2024, representing a growth of approximately 0.61%[23] - Net profit for the first three quarters of 2025 was ¥468,057,810.10, down from ¥510,285,014.19 in 2024, reflecting a decline of approximately 8.27%[24] - Total revenue for the first three quarters of 2025 reached ¥8,563,322,286.31, an increase from ¥8,365,256,571.78 in the same period of 2024, reflecting a growth of approximately 2.4%[27] - Basic and diluted earnings per share for the current period were both ¥0.40, down from ¥0.44 in the previous year[25] - The total comprehensive income attributable to the parent company for the first three quarters of 2025 was ¥459,603,789.62, a decrease from ¥514,800,610.01 in 2024[25] Assets and Liabilities - Total assets at the end of the quarter were ¥15,317,639,964.13, a decrease of 4.10% from the end of the previous year[5] - The company's total assets decreased to ¥15,317,639,964.13 from ¥15,972,478,068.00, a decline of approximately 4.09%[21] - Total liabilities decreased to ¥6,562,369,900.01 from ¥7,393,464,632.58, representing a reduction of about 11.24%[20] - The equity attributable to shareholders increased to ¥8,510,481,174.57, up 2.03% from the end of the previous year[5] - The company's equity attributable to shareholders increased to ¥8,510,481,174.57 from ¥8,341,353,163.16, showing an increase of approximately 2.03%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,644,663,551.07, an increase of 12.99%[4] - Net cash flow from operating activities for the first three quarters of 2025 was ¥1,644,663,551.07, compared to ¥1,455,579,860.77 in 2024, indicating an increase of about 12.9%[28] - The company reported a net cash outflow from investing activities of ¥198,673,150.61 in 2025, worsening from a net outflow of ¥120,299,452.25 in 2024[28] - Cash and cash equivalents at the end of Q3 2025 amounted to ¥1,392,479,467.78, up from ¥1,193,265,560.31 at the end of Q3 2024[29] - The company's cash and cash equivalents decreased to ¥51,258,502.22 from ¥69,771,512.72, a decline of approximately 26.66%[21] - As of September 30, 2025, the company's cash and cash equivalents amounted to RMB 1,516,606,462.28, an increase from RMB 1,497,647,788.41 at the end of 2024[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 54,361[11] - Zhejiang Haizheng Group Co., Ltd. holds 320,783,590 shares, accounting for 26.76% of the total shares[11] - The company has repurchased 35,711,300 shares, representing 2.98% of the total share capital, for future employee stock ownership plans[12] - The top ten shareholders include state-owned enterprises, with Zhejiang Haizheng Group being the largest shareholder[11] - The company has not identified any related party transactions among its shareholders[12] Expenses and Investments - Research and development expenses increased to ¥372,154,095.37 from ¥262,633,894.43, indicating a rise of about 41.73%[23] - The company reported a significant increase in sales expenses, which rose to ¥1,609,805,985.09 from ¥1,583,085,460.85, an increase of about 1.69%[23] - The company experienced a loss in investment income of ¥34,534,648.03 compared to a gain of ¥181,056,163.81 in the previous year[24] - The company plans to invest RMB 50 million in Nanjing Jisheng Aoma Biopharmaceutical Co., Ltd., holding 10.9890% of its shares[14] - The company has completed the transfer of shares to Growth River Investment Limited and Empire Gateway Investment Limited as part of a settlement agreement[13] Non-Recurring Items - Non-recurring gains and losses for the quarter totaled -¥7,428,970.04, with significant impacts from various adjustments and losses[8] - The company experienced a decrease in tax refunds received, totaling ¥13,156,921.23 in 2025 compared to ¥51,151,542.76 in 2024[27] - Cash inflow from financing activities in 2025 was ¥1,431,330,849.25, significantly lower than ¥3,452,000,000.00 in 2024[28] - The company paid out ¥323,720,682.87 in dividends and interest in 2025, compared to ¥112,231,571.14 in 2024, indicating a substantial increase in cash outflows[28] - The impact of exchange rate changes on cash and cash equivalents was a positive ¥231,228.83 in 2025, compared to a positive impact of ¥2,597,714.07 in 2024[28]

海正药业10月27日公告，2025年第三季度实现营业收入26.72亿元，同比增长1.57%；归属于上市公司股 东的净利润1.62亿元，同比增长102.14%；基本每股收益0.14元。前三季度实现营业收入79.23亿元，同 比增长0.61%；归属于上市公司股东的净利润4.61亿元，同比下降10.55%。 ...

证券代码：600267 证券简称：海正药业 公告编号：临 2025-60 号 会议召开时间：2025 年 11 月 3 日（星期一）15:00-16:00 会议召开地点：上海证券交易所上证路演中心 浙江海正药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 27 日（星期一）至 10 月 31 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过浙江海正药业股份有 限公司（以下简称"公司"）证券管理部邮箱 stock600267@hisunpharm.com 进行 提问。公司将在信息披露允许的范围内，于说明会上对投资者普遍关注的问题进 行回答。 公司将于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 年第三季度经 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has achieved a significant breakthrough in its internationalization strategy with the removal of the GMP non-compliance statement for its Taizhou factory by the EU, marking a key milestone in the company's internationalization 2.0 strategy [1][2] Group 1: Internationalization Strategy - The removal of the EU ban is crucial for Haizheng Pharmaceutical to consolidate its market position in the EU and rebuild international customer relationships [1] - The company is advancing a "global market integration" strategy, focusing on key regions such as Brazil, the Middle East and North Africa, and the CIS and Eastern Europe, while preparing for markets in Japan and Southeast Asia [1][2] - The comprehensive recovery of the EU market reduces the company's reliance on a single market and fosters deep strategic collaboration with markets in the US and Brazil, creating a new pattern of multi-regional and multi-sector collaboration [1][2] Group 2: Quality Management and Compliance - The EU's GMP certification is known as the "gold standard" in the pharmaceutical industry, and the initial non-compliance was due to deficiencies in handling hazardous materials and cross-contamination risks [2] - The company undertook a comprehensive quality improvement initiative, implementing a phased strategy to optimize various aspects of production, which led to the EU's partial withdrawal of the non-compliance statement [2][3] - The company's cGMP management system received high praise from the FDA and EDQM, indicating that it has reached an international first-class level [3] Group 3: Future Prospects and Competitive Edge - The lifting of the ban is expected to enhance the company's image, facilitate market access, and improve customer recognition, which will aid in promoting products internationally [3] - The company aims to optimize its product structure, focus on high-value and high-quality products, and expand market share, thereby enhancing profitability and core competitiveness in the global pharmaceutical supply chain [3][4] - The internationalization development reflects a broader transformation of the Chinese pharmaceutical industry from "manufacturing" to "intelligent manufacturing" and "quality manufacturing," showcasing the company's resilience in maintaining high-quality standards [5]

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has achieved a significant breakthrough in its internationalization strategy with the removal of the GMP non-compliance statement for its Taizhou factory by the EU, marking a key milestone in the company's internationalization 2.0 strategy [1] Group 1: Internationalization Strategy - The removal of the GMP non-compliance statement is crucial for consolidating the company's position in the EU market and rebuilding international customer relationships [1] - The company is advancing a "global market integration" strategy, focusing on key regions such as Brazil, the Middle East and North Africa, and the Commonwealth of Independent States and Eastern Europe, while also preparing for markets in Japan and Southeast Asia [1] - The comprehensive recovery of the EU market reduces the company's reliance on a single market and fosters deep strategic collaboration with markets like the US and Brazil, creating a new pattern of multi-regional and multi-sector collaboration [1] Group 2: Quality Improvement Efforts - The EU's GMP certification is known as the "gold standard" in the pharmaceutical industry, and the non-compliance statement issued in July 2019 highlighted deficiencies in handling hazardous materials and cross-contamination risks [2] - In response, the company initiated a comprehensive quality improvement campaign, implementing a phased strategy that prioritized workshops with better foundational conditions for systematic optimization across various aspects [2] - The company's efforts were recognized by the EU, leading to a partial withdrawal of the GMP non-compliance statement in April 2021 after a remote audit [2] Group 3: Regulatory Recognition - The company's significant investments in quality management have been acknowledged by the FDA and EDQM during inspections, with the cGMP management system receiving high praise for reaching international first-class standards [3] - Following positive inspection results, the company successfully requested the withdrawal of the non-compliance statement related to the production of cytotoxic and harmful active pharmaceutical ingredients at the Taizhou factory [3]

Core Viewpoint - The announcement from Haizheng Pharmaceutical regarding the revocation of the EU's GMP non-compliance declaration for its Taizhou factory marks a significant milestone in the company's internationalization strategy, enhancing its market position in Europe and facilitating deeper international customer relationships [1][2]. Group 1: Regulatory Compliance - The EU's GMP certification is recognized as the "gold standard" in the pharmaceutical industry, and the previous non-compliance declaration issued in July 2019 was due to deficiencies in handling hazardous substances and cross-contamination risks [2]. - Following the challenges posed by the EU ban, the company initiated a comprehensive quality improvement strategy, focusing on systematic optimization across various aspects of production [2]. Group 2: Strategic Developments - The revocation of the GMP non-compliance status is seen as a key milestone in the company's "Global Market Integration" strategy, which aims to reduce dependency on single markets and enhance strategic collaboration across multiple regions [1][3]. - The company is focusing on expanding its presence in Brazil, the Middle East and North Africa, and the CIS and Eastern Europe, while also preparing to enter the Japanese and Southeast Asian markets [1]. Group 3: Operational Improvements - The company's cGMP management system received high praise from the FDA and EDQM during inspections, indicating that the improvements made have reached international standards [3]. - The lifting of the EU ban is expected to enhance the company's image, remove market entry barriers, and promote high-value products, ultimately improving market share and profitability [3].

Group 1 - Xuedilong plans to invest no more than 400 million yuan to build an innovation industrial base in Changping District, Beijing, focusing on chromatography and mass spectrometry production lines [1] - The project aims to enhance research and production capabilities in carbon monitoring and measurement systems [1] Group 2 - Zejing Pharmaceutical's tri-specific antibody drug ZGGS34 has received clinical trial approval from the National Medical Products Administration for treating MUC17 positive advanced solid tumors [2] - The drug shows strong anti-tumor activity and good safety in preclinical studies [2] Group 3 - Aosaikang's new cMET inhibitor ASK202 will present clinical research data at the 2025 ESMO annual meeting, showing an objective response rate of 68.8% and a disease control rate of 93.8% in advanced non-small cell lung cancer patients [2][3] Group 4 - China Life expects a net profit of 156.785 billion to 177.689 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 50% to 70% [4] Group 5 - Silan Microelectronics plans to jointly invest 5.1 billion yuan to build a 12-inch high-end analog chip production line, with a total project investment of 20 billion yuan [5][6] Group 6 - New City intends to use 156.65 million yuan of remaining fundraising to invest in a "Building Green Energy and Zero Carbon Park" project, with a total investment of 257 million yuan [8] Group 7 - Yidao Information plans to acquire control of Guangzhou Langguo Electronic Technology and Shenzhen Chengwei Information through a combination of share issuance and cash payment [9] Group 8 - Xiling Information's controlling shareholder has received a notice of lifting restrictions, allowing normal business operations to resume [10] Group 9 - Dongpeng Holdings' first batch of rock slab products has passed the highest level 5A quality inspection, becoming one of the first companies to meet the new national standard [11] Group 10 - Aonlikang's levofloxacin tablets have received approval from the National Medical Products Administration, classified as a chemical drug of category 4 [15] Group 11 - Haizheng Pharmaceutical's Taizhou factory has had its GMP non-compliance declaration revoked by the EU, confirming compliance with EU GMP requirements [17][18] Group 12 - Hongfuhan's shareholder plans to reduce its stake by up to 1.5% through various trading methods due to asset integration and funding needs [19] Group 13 - Purang Co. plans to establish a wholly-owned subsidiary in Hong Kong to enhance its international competitiveness and service levels [20] Group 14 - Tianhe Magnetic Materials' subsidiary has signed an investment agreement for a project worth 850 million yuan focused on high-performance rare earth permanent magnets [22] Group 15 - Xiangfenghua reported a 64.64% year-on-year decline in net profit for the first three quarters, despite an 8.16% increase in revenue [23] Group 16 - Darui Electronics reported a 26.84% year-on-year increase in net profit for the first three quarters, with total revenue growing by 28.59% [24] Group 17 - Xiangsheng Medical reported a 4.56% year-on-year decline in net profit for the first three quarters, despite a 41.95% increase in net profit for the third quarter [25]

Core Viewpoint - The report by Zhiyan Consulting highlights the growth and future trends in China's chemical pharmaceutical industry, indicating a steady increase in production and market dynamics from 2025 to 2031 [1]. Industry Summary - According to the National Bureau of Statistics, the production of chemical pharmaceutical raw materials in China reached 263,000 tons in August 2025, with a cumulative production of 2,477,000 tons from January to August 2025, reflecting a growth of 3.1% [1]. - The report provides insights into the supply and demand situation in the chemical pharmaceutical industry, projecting future trends and market conditions [1]. Company Summary - Listed companies in the report include Heng Rui Medicine, East China Medicine, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical, indicating a diverse range of players in the market [1]. - The report emphasizes the importance of industry research and consulting services in aiding investment decisions, showcasing Zhiyan Consulting's expertise in providing comprehensive industry solutions [1].